Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity

CNS Spectrums

Volumn 19, Issue 1, 2014, Pages 50-61

  Pallanti, Stefano ^a,b,c   Hollander, Eric ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

impulsivity; Keywords Compulsivity; obsessive compulsive; OCD; pharmacotherapy; TMS; transcranial magnetic stimulation; treatment

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; HOX PROTEIN; MEMANTINE; NALTREXONE; ONDANSETRON; PAROXETINE; PLACEBO; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; CHOLERA TOXIN; DEXAMPHETAMINE; DOPAMINE 1 RECEPTOR; GRANISETRON; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RILUZOLE; SLIT PROTEIN; TOPIRAMATE;

ADDICTION; AMYGDALOID NUCLEUS; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; BODY DYSMORPHIC DISORDER; BRAIN FUNCTION; BRAIN REGION; COGNITIVE THERAPY; COMORBIDITY; COMPULSION; CORPUS STRIATUM; D1CT 7 GENE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE INCREASE; GENE; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HOX GENE; HUMAN; IMPULSE CONTROL DISORDER; MONOTHERAPY; NERVE CELL NETWORK; NEUROTRANSMITTER RELEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OBSESSIVE HOARDING; ORBITAL CORTEX; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SAPAP3 GENE; SAPAP4 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN PICKING DISORDER; SLITRK5 GENE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING; TRICHOTILLOMANIA; BASAL GANGLION; CLINICAL EFFECTIVENESS; COMPULSIVE PERSONALITY DISORDER; CONNECTOME; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; EXECUTIVE FUNCTION; GENE DELETION; IMPULSIVENESS; MOLECULARLY TARGETED THERAPY; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAPAP 3 GENE; SAPAP 4 GENE; SUBSTANCE ABUSE; THERAPY RESISTANCE; TREATMENT OUTCOME; WORKING MEMORY;

COMORBIDITY; COMPULSIVE BEHAVIOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; IMPULSIVE BEHAVIOR; NERVE NET; OBSESSIVE-COMPULSIVE DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84896719236     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000618     Document Type: Review

References (116)

1. Kupfer DJ, First MB, Regier DA. A Research Agenda for DSM-V. Arlington, VA: American Psychiatric Publishing; 2008.
2. Mataix-Cols D, Boman M, Monzani B, et al. Population-based, multigenerational family clustering study of obsessive-compulsive disorder. JAMA Psychiatry. 2013;70(7):709-717.
3. Van Grootheest DS, Van Den Berg SM, Cath DC, Willemsen G, Boomsma DI. Marital resemblance for obsessive-compulsive, anxious and depressive symptoms in a population-based sample. Psychol Med. 2008;38(12):1731-1740.
4. Stewart SE, Yu D, Scharf JM, et al. D. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry. 2012;18(7):788-798.
5. Stewart SE, Mayerfeld C, Arnold PD. Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene SLC1A1. Am J Med Genet B Neuropsychiatr Genet. 2013;162(4):367-379.
6. Abramowitz JS, Deacon B, Olatunji B, et al. Assessment of obsessive-compulsive symptom dimensions: development and evaluation of the Dimensional Obsessive-Compulsive Scale. Psychol Assess. 2010;22:180-198.
7. Capecchi MR. Hox genes and mammalian development. Cold Spring Harb Symp Quant Biol. 1997;62:273-281.
8. Greer JM, Capecchi MR. Hoxb8 is required for normal grooming behavior in the mouse. Neuron. 2002;33:23-34.
9. Chen SK, Tvrdik P, Peden E, et al. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell. 2010;141(5):775-785.
10. Antony JM. Grooming and growing with microglia. Sci Signal. 2010;3(147):jc8.
11. Wan Y, Feng G, Calakos N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci. 2011;31(46):16685-16691.
12. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature. 2007;448:894-900.
13. Wan Y, Ade KK, Caffall Z, et al. Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessivecompulsive disorder. Biol Psychiatry. In press. DOI: 10.1016/j.biopsych.2013.01.008.
14. Shmelkov SV, Hormigo A, Jing D, et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat Med. 2010;16(5):598-602.
15. Campbell KM, De Lecea L, Severynse DM, et al. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci. 1999;19:5044-5053.
16. Nordstrom EJ, Burton FH. A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry. 2002;7:617-625, 524.
17. McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000;877:23-30.
18. Taj MJRJ, Viswanath B, Purushottam M, et al. DRD4 gene and obsessive compulsive disorder: do symptom dimensions have specific genetic correlates? Prog Neuropsychopharmacol Biol Psychiatry. 2013;41:18-23.
19. Cannistraro PA, Rauch SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull. 2003;37:8-25.
20. Mataix-Cols D, Cullen S, Lange K, et al. Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers. Biol Psychiatry. 2003;53:482-493.
21. Van Den Heuvel OA, Veltman DJ, Groenewegen HJ, et al. Amygdala activity in obsessive-compulsive disorder with contamination fear: a study with oxygen-15 water positron emission tomography. Psychiatry Res. 2004;132:225-237.
22. Simon D, Kaufmann C, Musch K, et al. Fronto-striato-limbic hyperactivation in obsessive-compulsive disorder during individually tailored symptoms provocation. Psychophysiology. 2010;47:728-738.
23. Le Doux JE. Synaptic Self: How Our Brains Become Who We Are. New York: Viking Penguin; 2002.
24. Davis M. The role of the amygdala in fear and anxiety. Annu Rev Neurosci. 1992;15(1):353-375.
25. Sookman D, Pinard G. Overestimation of threat and intolerance of uncertainty in obsessive compulsive disorder. In: Frost RO, Steketee G, eds. Cognitive Approaches to Obsessions and Compulsions: Theory, Assessment and Treatment. Oxford, UK: Elsevier; 2002:63-89.
26. Stein DJ. Advances in understanding the anxiety disorders: the cognitive-affective neuroscience of "false alarms". Ann Clin Psychiatry 2006;18:173-182.
27. Saxena S, Brody AL, Schwartz JM, et al. Neuroimaging and frontalsubcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry. 1998;173(35):26-37.
28. Menzies L, Chamberlain SR, Laird AR, et al. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev. 2008;32(3):525-549.
29. Depue R, Collins P. Neurobiology of the structure of personality: dopamine, facilitation of incentive motivation, and extraversion. Behav Brain Sci. 1999;22(3):491-517.
30. Harrison BJ, Soriano-Mas C, Pujol J, et al. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 2009;66(11):1189-1200.
31. Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010;35(1):4-26.
32. Szechtman H, Woody E. Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev. 2004;111(1):111-127.
33. Endrass T, Kloft L, Kaufmann C, et al. Approach and avoidance learning in obsessive-compulsive disorder. Depress Anxiety. 2011;28(2):166-172.
34. Beaulieu C. The basis of anisotropic water diffusion in the nervous system-a technical review. NMR Biomed. 2002;15(7-8):435-455.
35. Sporns O. Brain networks and embodiment. In: Mesquita B, Feldman B, eds. Mind in Context. New York: Guilford Press; 2010:42-64.
36. Banks SJ, Eddy KT, Angstadt M, et al. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci. 2007;2(4):303-312.
37. Kim MJ, Whalen PJ. The structural integrity of an amygdalaprefrontal pathway predicts trait anxiety. J Neurosci. 2009;29(37):11614-11618.
38. Phillips ML, Drevets WC, Rauch SL, et al. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol Psychiatry. 2003;54(5):515-528.
39. Brody AL, Saxena S, Schwartz JM, et al. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res. 1998;84(1):1-6.
40. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):563-586.
41. Menzies L, Williams GB, Chamberlain SR, et al. White matter abnormalities in patients with obsessive-compulsive disorder and their first-degree relatives. Am J Psychiatry. 2008;165(10):1308-1315.
42. Del Casale A, Kotzalidis GD, Rapinesi C, et al. Functional neuroimaging in obsessive-compulsive disorder. Neuropsychobiology. 2011;64(2):61-85.
43. Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012;16(1):43-51.
44. Aouizerate B, Guehl D, Cuny E, et al. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol. 2004;72(3):195-221.
45. Maltby N, Tolin DF, Worhunsky P, et al. Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessivecompulsive disorder: an event-related fMRI study. Neuroimage. 2005;24(2):495-503.
46. Fitzgerald KD, Welsh RC, Gehring WJ, et al. Error-related hyperactivity of the anterior cingulate cortex in obsessivecompulsive disorder. Biol Psychiatry. 2005;57(3):287-294.
47. Kringelbach ML. The human orbitofrontal cortex: linking reward to hedonic experience. Nat Rev Neurosci. 2005;6(9):691-702.
48. Remijnse PL, Nielen MM, Van Balkom AJ, et al. Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. Arch Gen Psychiatry. 2006;63(11):1225-1236.
49. Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science. 2008;321(5887):421-422.
50. Figee M, Vink M, De Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry. 2011;69(9):867-874.
51. Rauch SL, Dougherty DD, Cosgrove GR, et al. Cerebral metabolic correlates as potential predictors of response to anterior cingulotomy for obsessive compulsive disorder. Biol Psychiatry. 2001;50(9):659-667.
52. Hendler T, Goshen E, Tzila Zwas S, et al. Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Research: Neuroimaging. 2003;124(2):87-103.
53. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49(9):739.
54. Shanahan NA, Velez LP, Masten VL. Essential Role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry. 2011;70(11):1039-1048.
55. Melloni M, Urbistondo C, Sedeño L, et al. The extended frontostriatal model of obsessive compulsive disorder: convergence from event-related potentials, neuropsychology and neuroimaging. Front Hum Neurosci. 2012;6:259.
56. Fineberg NA, Pallanti S, Reghunandanan S, Baldwin DS, Leonard BE (eds). Anxiety Disorders. Mod Trends Pharmacopsychiatry. Basel, Karger, 2003:29:164-177.
57. Pallanti S, Hollander E, Bienstock C, et al. Treatment nonresponse in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181-191.
58. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002;63(9):796.
59. Pallanti S, Grassi G. Citalopram pulse loading for severe treatment-resistant OCD: a case series of acute response, one year follow-up and tolerability. J Depress Anxiety. In press. DOI: 10.4172/2167-1044. S10-002.
60. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;26(1):79-83.
61. Ross S, Fallon BA, Petkova E, Feinstein S, Liebowitz MR. Long-term follow-up study of patients with refractory obsessivecompulsive disorder. J Neuropsychiatry Clin Neurosci. 2008;20(4):450-457.
62. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in treatment-resistant obsessivecompulsive disorder. CNS Drugs. 2009;23(12):1047-1055.
63. Askari N, Moin M, Sanati M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2012;26(10):883-892.
64. Hollander E, Pallanti S. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647-1664, Neuro psychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology, Edited by KL Davis, D. Charney, JT Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002.
65. Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv. 2003;54(8):1111-1118.
66. Koran LM, Aboujaoude E, Gamel NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatmentresistant obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(11):1530-1535.
67. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial. CNS Spectr. 2010;15(11):613-617.
68. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatmentresistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2007;17(6):761-767.
69. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebocontrolled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716-721.
70. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29(1):51-55.
71. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs. 2011;25(7):585-596.
72. Feusner JD, Kerwin L, Saxena S & Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology bulletin. 2009;42(1):81.
73. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. In press. DOI: 10.1038/npp. 2013.
74. Farrell LJ, Waters AM, Boschen MJ, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of d-cycloserine augmented behavior therapy. Depress Anxiety. 2013;30(8):723-731.
75. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessivecompulsive disorder. J Clin Psychiatry. 2004;65(14):6-10.
76. Saxena S. Pharmacotherapy of compulsive hoarding. J Clin Psychol. 2011;67(5):477-484.
77. Ecker W, Kupfer J, Gönner S. Incompleteness as a link between obsessive-compulsive personality traits and specific symptom dimensions of obsessive-compulsive disorder. Clin Psychol Psychother. In press. DOI: 10.1002/cpp. 1842.
78. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Arlington, VA: American Psychiatric Association; 2000.
79. Grant JE, Odlaug BL, Potenza MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv Rev Psychiatry. 2007;15(2):80-85.
80. Lange LA, Kampov-Polevoy AB, Garbutt JC. Sweet liking and high novelty seeking: independent phenotypes associated with alcohol-related problems. Alcohol Alcohol. 2010;45(5):431-436.
81. Schlosser S, Black DW, Blum N, Goldstein RB. The demography, phenomenology and family history of 22 persons with compulsive hair pulling. Ann Clin Psychiatry. 1994;6(3):147-152.
82. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association.
83. Lochner C, Hemmings SM, Kinnear CJ, et al. Cluster analysis of obsessive-compulsive symptomatology: identifying obsessivecompulsive disorder subtypes. Isr J Psychiatry Relat Sci. 2008;45(3):164-176.
84. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000;32(Suppl: i-iv):1-112.
85. Laine TP, Ahonen A, Rasanen P, et al. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics. Alcohol Alcohol. 2001;36(3):262-265.
86. Laine TP, Ahonen A, Rasanen P, et al. Dopamine transporter density and novelty seeking among alcoholics. J Addict Dis. 2001;20(4):91-96.
87. Retz W, Rosler M, Supprian T, et al. Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. J Neural Transm. 2003;110(5):561-572.
88. Ray LA, Bryan A, Mackillop J, et al. The dopamine D Receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol. 2009;14(2):238-244.
89. Demetrovics Z, Varga G, Szekely A, et al. Association between novelty seeking of opiate-dependent patients and the catechol-O-methyl transferase Val (158) Met polymorphism. Compr Psychiatry. 2010;51(5):510-515.
90. Loos M, Pattij T, Janssen MC, et al. Dopaminereceptor D1/D5 gene expression in the medial prefrontal cortex predicts impulsive choice in rats. Cereb Cortex. 2010;20(5):1064-1070.
91. O'Sullivan RL, Philips KA, Keuthen NJ. Near fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine. Psychosomatics. 1999;40(1):79-81.
92. Bloch MH, Landeros-Weisenberger A, Dombrowski P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry. 2007;62(8):839-846.
93. Snorrason I, Belleau EL, Woods DW. How related are hair pulling disorder (trichotillomania) and skin picking disorder? A review of evidence for comorbidity, similarities and shared etiology. Clin Psychol Rev. 2012;32(7):618-629.
94. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2011;2:70.
95. Timpano KR, Rubenstein LM, Murphy DL. Phenomenological features and clinical impact of affective disorders in OCD: a focus on the bipolar disorder and OCD connection. Depress Anxiety. 2012;29(3):226-233.
96. Centorrino F, Hennen J, Mallya G, et al. Clinical outcome in patients with bipolar I disorder, obsessive compulsive disorder or both. Hum Psychopharmacol. 2006;21(3):189-193.
97. Hollander E, Buchsbaum MS, Haznedar MM, et al. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulate metabolism. Neuropsychobiology. 2008;58(1):37-47.
98. Dorrego MF, Canevaro L, Kuzis G, Sabe L, Starkstein SE. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder preliminary findings. J Neuropsychiatry Clin Neurosci. 2002;14(3):289-295.
99. Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessivecompulsive disorder. J Clin Psychiatry. 2005;66(3):353-359.
100. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008;18(6):455-461.
101. Jaafari N, Rachid F, Rotge JY, et al. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: a review. World J Biol Psychiatry. 2012;13(3):164-177.
102. Greenberg BD, George MS, Martin JD, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessivecompulsive disorder: a preliminary study. Am J Psychiatry. 1997;154(6):867-869.
103. Sachdev PS, McBride R, Loo CK, et al. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. J Clin Psychiatry. 2001;62(12):981-984.
104. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(7):1143-1145.
105. Kang JI, Kim CH, Namkoong K, et al. A randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(12):1645-1651.
106. Sarkhel S, Sinha VK, Praharaj SK. Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression. J Anxiety Disord. 2010;24(5):535-539.
107. Prasko J, Pasková B, Záleský R, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder: a randomized, double blind, sham controlled study. Neuro Endocrinol Lett. 2006;27(3):327-332.
108. Sachdev PS, Loo CK, Mitchell PB, et al. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med. 2007;37(11):1645-1649.
109. Mantovani A, Lisanby SH, Pieraccini F, et al. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol. 2006;9(1):95-100.
110. Mantovani A, Leckman JF, Grantz H, et al. Repetitive transcranial stimulation of the supplementary motor area in the treatment of Tourette syndrome: report of two cases. Clin Neurophysiol. 2007;118(10):2314-2315.
111. Mantovani A, Simpson HB, Fallon BA, et al. Randomized shamcontrolled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2010;13(2):217-227.
112. Mantovani A, Westin G, Hirsch J. Functional magnetic resonance imaging guided transcranial magnetic stimulation in obsessivecompulsive disorder. Biol Psychiatry. 2010;67(7):e39-e40.
113. Alptekin K, Degermenci B, Kivircik B, et al. Tc-99m HMPAO brain perfusion SPECT in drug-free obsessive-compulsive patients without depression. Psychiatry Res. 2001;107(1):51-56.
114. Baxter LR, Schwartz JM, Mazziotta JC, et al. Cerebral glucose metabolic rates in non-depressed patients with obsessivecompulsive disorder. Am J Psychiatry. 1988;145(12):1560-1563.
115. Swedo SE, Schapiro MB, Grady CL, et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 1989;46(6):518-523.
116. Ruffini C, Locatelli M, Lucca A, et al. Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry. 2009;11(5):226-230.